Trial in Progress: A randomized double-blind phase 3 trial comparing vintafolide + pegylated liposomal doxorubicin (PLD) versus PLD + placebo in patients with platinum-resistant ovarian cancer (PROCEED)

Naumann, R. Wendel

446 - Poster Session B
Trial in Progress: A randomized double-blind phase 3 trial comparing vintafolide + pegylated liposomal doxorubicin (PLD) versus PLD + placebo in patients with platinum-resistant ovarian cancer (PROCEED)

Sunday, March 23, 2014: 6:20 PM

West Exhibit Hall (Tampa Convention Center)

R. W. Naumann¹, L. Gilbert², A. Habbe³, H. Ma³, S. Ghamande⁴ and I. B. Vergote⁵
¹Levine Cancer Institute, Charlotte, NC, ²McGill University Health Centre, Montreal, QC, Canada, ³Endocyte, Inc, West Lafayette, IN, ⁴Georgia Regents University, Augusta, GA, ⁵University Hospital Leuven, Leuven, Belgium

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

446 - Poster Session B
Trial in Progress: A randomized double-blind phase 3 trial comparing vintafolide + pegylated liposomal doxorubicin (PLD) versus PLD + placebo in patients with platinum-resistant ovarian cancer (PROCEED)

446 - Poster Session B Trial in Progress: A randomized double-blind phase 3 trial comparing vintafolide + pegylated liposomal doxorubicin (PLD) versus PLD + placebo in patients with platinum-resistant ovarian cancer (PROCEED)

446 - Poster Session B
Trial in Progress: A randomized double-blind phase 3 trial comparing vintafolide + pegylated liposomal doxorubicin (PLD) versus PLD + placebo in patients with platinum-resistant ovarian cancer (PROCEED)